WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory...
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Results Support Potential for Extended...
WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory...
- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target;...
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and Aclaris Therapeutics (ACRS – Research Report) with...
Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Aclaris Therapeutics today. The company’s shares opened today at $1.85.Elevate Your Investing Strategy: Take advantage of TipRanks...
In a report released today, Martin Fan from Wedbush maintained a Buy rating on Aclaris Therapeutics, with a price target of $8.00. The company’s shares closed yesterday at $1.81.Elevate Your Investing...
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Aclaris Therapeutics, with a price target of $6.00. The company’s shares closed yesterday at $1.81.Elevate Your Investing...